These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8318688)

  • 1. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP; Sands JM
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
    Besarab A; Flaharty KK; Erslev AJ; McCrea JB; Vlasses PH; Medina F; Caro J; Morris E
    J Am Soc Nephrol; 1992 Mar; 2(9):1405-16. PubMed ID: 1627763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Pais MJ; Gaspar A; Santana A; Bruges M; Simões J
    Perit Dial Int; 1993; 13 Suppl 2():S541-3. PubMed ID: 8399660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
    Cuero CJ; Pérez Guardia E; de Rivera C
    Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.
    Besarab A
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):13-22. PubMed ID: 8352267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 10. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration.
    Granolleras C; Branger B; Shaldon S; Nonnast-Daniel B; Koch KM; Pollok M; Baldamus CA
    Contrib Nephrol; 1991; 88():144-8; discussion 149-51. PubMed ID: 2040176
    [No Abstract]   [Full Text] [Related]  

  • 11. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit.
    Balkovetz DF; Frazier C; Sanders PW
    Nephrol Dial Transplant; 1998 Nov; 13(11):2979-80. PubMed ID: 9829525
    [No Abstract]   [Full Text] [Related]  

  • 12. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD.
    Saleh A; Krane NK; Caballero M; Starks E
    Adv Perit Dial; 1991; 7():288-91. PubMed ID: 1680448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 14. The treatment of anemia with low-dose recombinant human erythropoietin.
    Aronoff GR; Duff DR; Sloan RS; Brier ME; Maurice B; Erickson B; Golper TA
    Am J Nephrol; 1990; 10 Suppl 2():40-3. PubMed ID: 2260617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous recombinant erythropoietin in preterminal renal insufficiency.
    Van Geet C; Van Dyck M; Proesmans W
    Eur J Pediatr; 1994 Feb; 153(2):129-32. PubMed ID: 8157020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
    Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
    Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M; Miyazono K; Urabe A; Takaku F
    Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta.
    Ostrvica E; Mesic E; Ostrvica D; Delic J; Delic-Custendil S; Hukic F
    Med Arh; 2010; 64(1):4-6. PubMed ID: 20422814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.